TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02685150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Tri-Modal Imaging
Description: Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Tri-Modal Imaging
Description: Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Tri-Modal Imaging
Description: Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Tri-Modal Imaging
Description: Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of gastric juice
Description: Analysis of gastric juice including routine, biochemical and microbiological analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of gastric juice
Description: Analysis of gastric juice including routine, biochemical and microbiological analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of gastric juice
Description: Analysis of gastric juice including routine, biochemical and microbiological analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of gastric juice
Description: Analysis of gastric juice including routine, biochemical and microbiological analysis.
Study: NCT02844738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [StroMed + platelet rich plasma (PRP)]
Description: Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Days 7 and 14 \[PRP\]
Study: NCT02287246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release liposomal bupivacaine (Exparel)
Description: 20mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 20mL
Study: NCT03682575

Intervention type: OTHER
Intervention: Enrollment
Description: All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.

Intervention type: OTHER
Intervention: Enrollment
Description: All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
Study: NCT03711448

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: HAQ ; SF-36 ; FACIT-fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: HAQ ; SF-36 ; FACIT-fatigue

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: Additional blood samples for immunomonitoring

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Additional blood samples for immunomonitoring
Study: NCT03616886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study: NCT01618955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VIBEX MTX
Description: Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
Study: NCT01804595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Study: NCT01219075

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mammography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: mammography
Description: Correlative studies
Study: NCT03724097

Intervention type: OTHER
Intervention: RNA sequencing
Description: Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.

Intervention type: OTHER
Intervention: RNA sequencing
Description: Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.

Intervention type: OTHER
Intervention: RNA sequencing
Description: Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
Study: NCT03616886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI4736
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9447
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study: NCT03724097

Intervention type: OTHER
Intervention: Transcriptome analysis
Description: Analysis of RNA-seq data using the Oncobox algorithm.
Study: NCT01804595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-Message Reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-Message Reminders

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen and Text Message Reminders
Study: NCT01993810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT01804595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study: NCT01804595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study: NCT01804595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study: NCT03724097

Intervention type: DRUG
Intervention: target drug with the score above 0,1
Description: target drug with the score above 0,1
Study: NCT01993810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT01769404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Study: NCT03724097

Intervention type: DRUG
Intervention: target drug with the score equal or below 0,1
Description: target drug with the score equal or below 0,1

Intervention type: DRUG
Intervention: non-target drug
Description: non-target drug

Intervention type: DRUG
Intervention: palliative care
Description: palliative care
Study: NCT03167398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
Study: NCT02455323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibitory
Description: According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulative
Description: This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined treatment
Description: Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group.
Description: The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
Study: NCT01783236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: 1000mg IV Ofirmev given every six hours for a total of four doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
Study: NCT01183637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kensey Nash Corp. Cartilage Repair Device
Description: To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
Study: NCT01269034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 1.25 mcg before the boost sub-cutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid and long acting insulin
Description: Depends on their Carbohydrate ratio and body needs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting insulin + rapid acting + 1.25 mcg Exenatide
Description: Depends on their body needs.
Study: NCT01589094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin (DD GC)
Description: Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
Study: NCT04411238

Intervention type: OTHER
Intervention: interview
Description: interview

Intervention type: OTHER
Intervention: interview
Description: interview

Intervention type: OTHER
Intervention: interview
Description: interview
Study: NCT04095208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of Nivolumab + Relatlimab
Description: A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[80 mg\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\].
Study: NCT00609440

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapeutic treatment
Description: At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
Study: NCT02988804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment).
Study: NCT04170140

Intervention type: OTHER
Intervention: No intervention
Description: Questionnaire
Study: NCT00744367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: \>1500 mg/day or maximum tolerated dose (MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: \>1500 mg/day or maximum tolerated dose (MTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: \>1500 mg/day or maximum tolerated dose (MTD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: \>= 30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: \>= 30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: \>= 30 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: taspoglutide
Description: 10 mg sc once weekly;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10 mg sc once weekly;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: taspoglutide
Description: 20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
Study: NCT02330991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT00479362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin is either interrupted or uninterrupted prior to device implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin is either interrupted or uninterrupted prior to device implantation

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin
Description: Aspirin is continued without interruption prior to device implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent pacemaker
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study: NCT00239980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparin
Description: 50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
Study: NCT02742246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual clinician-provided CBT
Description: Individual clinician-provided CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT
Description: CBT computer program assisted therapy
Study: NCT00239980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparin
Description: 50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparin
Description: 50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
Study: NCT00478140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04551924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropin
Description: Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
Study: NCT03701100

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS
Study: NCT02916082

Intervention type: PROCEDURE
Intervention: Cervical length measurement
Description: Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
Study: NCT01993810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon Beam Radiation Therapy
Description: Undergo photon beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03307343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.